WillItSurvive
No grouping · Ireland

Davion Healthcare Plc

Pre-revenue Irish firm selling at-home thermography screening kits, seeking Nasdaq listing.

Little protection left
Assessed 30 July 2026 · Evidence as of 30 July 2026
Not much stands between this business and its pressures.
On the recordSince 30 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Resolution of DAVI Nasdaq trading status, still listed as pending 7 months after F-1 effectiveness
The call

Davion is a pre-trading, pre-revenue shell whose thermography products lack the clinical or regulatory backing that its AI-driven rivals already have.

Davion makes thermal imaging technology designed to screen for breast cancer without mammography. The company has not shipped any products, has no paying customers, and the FDA has stated that thermal imaging cannot replace mammography, which is a big problem since that was the original pitch. Competitors like Niramai and Cyrcadia already have FDA clearance and clinical studies backing their thermal approaches, while the major breast imaging companies (Hologic, GE Healthcare, Siemens) have deliberately stayed out of thermal imaging because of regulatory and legal risk. The one thing that could change everything is whether Davion can actually start trading on Nasdaq and then raise money through bonds before shipping anything, which would unlock access to capital, but as of mid-2026 the company is still waiting to begin trading even though its paperwork was approved in late 2025.

Why
01
AI pressure: Niramai (Thermalytix) and Cyrcadia Health (iTBra). Both rivals already run AI-thermal screening with peer-reviewed data or FDA clearance; Davion has neither. Could AI do the core job? Yes, likely.
02
Bigger players: Hologic, GE Healthcare, Siemens Healthineers. These imaging giants stay out of thermography screening, leaving the category open rather than contested. Could a giant copy it? Yes, easily.
03
What protects it. None apparent: no FDA clearance, no clinical data, no confirmed trading or revenue to defend.
What would change this call
DAVI stock actually begins trading on Nasdaq with a real price. Shows whether Davion can achieve functioning public market status at all.
Davion reports first confirmed BreastCheck product revenue or unit sales. Shows whether the direct commercialization pivot produces any real customers.
Davion's £100M bond programme or Humaskan/Solar Medical acquisitions close or collapse. Shows whether debt-funded M&A proceeds despite no product revenue.
Key numbers
  • F-1 effective Nov 28, 2025; DAVI stock still 'Pending' (2026-06-23)
  • Licensing deal signed then terminated within about 60 days (2026-06-22)
  • Reported cash and equivalents: $12 (2026-06-25)
Named risks
  • Nasdaq trading status unresolved 7+ months after F-1 became effective Nov 28, 2025. Severity: high
  • Core thermography technology explicitly stated by FDA to be no substitute for mammography. Severity: high
  • Debt-funded M&A (up to £100M bond programme, June 2026) planned before confirmed product revenue. Severity: high
  • Licensing strategy reversed within about 60 days (Odyssey deal April to June 2026) signals execution instability. Severity: medium
  • No independent clinical validation versus better-credentialed peers Niramai and Cyrcadia Health. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Niramai (Thermalytix)gaining onPublished peer-reviewed clinical validation of AI thermal screening since 2018-07
Cyrcadia Healthgaining onFDA 510(k)-cleared iTBra predicate device, iFlytek-backed, confirmed as of 2024-07
Hologic, GE Healthcare, Siemens HealthineerscontestingAvoid thermography category over liability/regulatory risk, not structural lock-out
Questions people ask
Is Davion Healthcare (DAVI) actually trading on Nasdaq yet?
No. Davion's F-1 became automatically effective on November 28, 2025, but as of June 23, 2026 stockanalysis.com still lists DAVI as 'will go public soon, exact IPO date unknown' with price shown as Pending, meaning no confirmed trading nearly seven months after effectiveness.
Is Davion Healthcare profitable?
No. Davion is pre-revenue. Its flagship BreastCheck product was slated for commercial launch 'by end of H1 2026' per December 2025 press releases, but as of June 2026 the company was still restructuring its go-to-market model rather than confirming sales or revenue.
Who are Davion Healthcare's biggest competitors in home breast screening?
Niramai's Thermalytix has published peer-reviewed clinical validation since 2018, and Cyrcadia Health's iTBra is an FDA 510(k)-cleared predicate device backed by iFlytek as of 2024. Both hold clinical or regulatory credentials Davion's self-declared Class I BreastCheck lacks.
Is thermography, Davion's core technology, FDA approved for breast cancer screening?
No. The FDA stated on October 6, 2023 that breast thermograms are 'no substitute for mammogram' and not approved as a standalone screening tool. A 2026 study cited by vbcf.org found thermography carries a false-positive rate around 56%.
Why did Davion Healthcare end its Odyssey Group licensing deal for BreastCheck?
Odyssey Group secured an exclusive global sub-license for BreastCheck on April 24, 2026, but Davion terminated its global licensing and distribution arrangements just two months later on June 22, 2026, pivoting instead to a direct commercialization model via a Solar Medical acquisition.
Could AI replace Davion Healthcare's product?
Davion's own BreastCheck already relies on AI to analyze smartphone photos of thermal-sensitive film, but that image-classification layer is a commodity capability. Niramai's Thermalytix has run comparable AI-based thermal analysis with peer-reviewed clinical validation published since 2018, exposing Davion to being outcompeted rather than replaced.
Timeline
  • 2026-06-25Proposed acquisition of Humaskan Ltd and UK finance subsidiary for up to £100M bond programme
  • 2026-06-22Terminated global BreastCheck licensing deals, pivoted to direct model, agreed Solar Medical acquisition
  • 2026-04-24Odyssey Group secured exclusive global sub-license for BreastCheck
  • 2025-12-02Appointed CFO Andreas Ttofi and non-exec director Jan Dulman
  • 2025-11-28F-1 registration statement became automatically effective under Section 8(a)
  • 2025-08-04Filed F-1 registration statement for proposed Nasdaq direct listing
  • 2024-09Re-domiciled corporate jurisdiction from Cyprus to Ireland
  • 2023-11-09Granted NeuRX Health a $120M BreastCheck manufacturing and distribution license (vendor-claimed)
  • 2022-11-29Davion Healthcare Plc incorporated in Cyprus
Revision history
30 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Optimum CommunicationsWarner Bros. DiscoveryInflection AI
More companies little protection left →
Sources